Antifungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: A meta-analysis of randomized, placebo-controlled trials

Critical Care Medicine

Volumn 34, Issue 4, 2006, Pages 1216-1224

  Vardakas, Konstantinos Z ^a   Samonis, George ^b   Michalopoulos, Argyris ^a,c   Soteriades, Elpidoforos S ^a,d   Falagas, Matthew E ^a,c,e  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

^c HENRY DUNANT HOSPITAL   (Greece)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amphotericin B; Azole; Fluconazole; Itraconazole; Ketoconazole; Polyene; Prevention; Surgery; Transplantation

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; INSULIN; ITRACONAZOLE; KETOCONAZOLE; NEOMYCIN; NORADRENALIN; OKT 3; PLACEBO; POLYMYXIN B; PYRROLE DERIVATIVE; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; CANDIDA ALBICANS; CANDIDIASIS; CLINICAL TRIAL; COCHRANE LIBRARY; DATA ANALYSIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; INTENSIVE CARE UNIT; LIVER TOXICITY; MEDLINE; META ANALYSIS; MORTALITY; MYCOSIS; NAUSEA AND VOMITING; POSTOPERATIVE INFECTION; PREOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZATION; REVIEW; SCISEARCH; STATISTICAL SIGNIFICANCE; SURGICAL PATIENT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTIFUNGAL AGENTS; AZOLES; CANDIDIASIS; HUMANS; INTENSIVE CARE; INTENSIVE CARE UNITS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 33645833237     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000208357.05675.C3     Document Type: Review

References (68)

1. Castagnola E, Machetti M, Bucci B, et al: Antifungal prophylaxis with azole derivatives. Clin Microbiol Infect 2004; 10(Suppl 1):86-95
2. Lipsett PA: Clinical trials of antifungal prophylaxis among patients in surgical intensive care units: Concepts and considerations. Clin Infect Dis 2004; 39(Suppl 4):S193-S199
3. McKinnon PS, Goff DA, Kern JW, et al: Temporal assessment of Candida risk factors in the surgical intensive care unit. Arch Surg 2001; 136:1401-1408
4. Voss A, Hollis RJ, Pfaller MA, et al: Investigation of the sequence of colonization and candidemia in nonneutropenic patients. J Clin Microbiol 1994; 32:975-980
5. Reagan DR, Pfaller MA, Hollis RJ, et al: Characterization of the sequence of colonization and nosocomial candidemia using DNA fingerprinting and a DNA probe. J Clin Microbiol 1990; 28:2733-2738
6. Calandra T, Marchetti O: Clinical trials of antifungal prophylaxis among patients undergoing surgery. Clin Infect Dis 2004; 39(Suppl 4):S185-S192
7. Paya CV: Prevention of fungal infection in transplantation. Transpl Infect Dis 2002; 4(Suppl 3):46-51
8. Swoboda SM, Merz WG, Lipsetta PA: Candidemia: The impact of antifungal prophylaxis in a surgical intensive care unit. Surg Infect (Larchmt) 2003; 4:345-354
9. Rocco TR, Reinert SE, Simms HH: Effects of fluconazole administration in critically ill patients: Analysis of bacterial and fungal resistance. Arch Surg 2000; 135:160-165
10. Zwaveling JH, Maring JK, Klompmaker IJ, et al: Selective decontamination of the digestive tract to prevent postoperative infection: A randomized placebo-controlled trial in liver transplant patients. Crit Care Med 2002; 30:1204-1209
11. Riedl S, Peter B, Geiss HK, et al: Microbiological and clinical effects of selective bowel decontamination in transthoracic resection of carcinoma of the esophagus and cardia. Chirurg 2001; 72:1160-1170
12. Barret JP, Jeschke MG, Herndon DN: Selective decontamination of the digestive tract in severely burned pediatric patients. Burns 2001; 27:439-445
13. Wijers OB, Levendag PC, Harms ER, et al: Mucositis reduction by selective elimination of oral flora in irradiated cancers of the head and neck: A placebo-controlled double-blind randomised study. Int J Radiat Oncol Biol Phys 2001; 50:343-352
14. Lingnau W, Berger J, Javorsky F, et al: Selective intestinal decontamination in multiple trauma patients: Prospective, controlled trial. J Trauma 1997; 42:687-694
15. Schardey HM, Joosten U, Finke U, et al: The prevention of anastomotic leakage after total gastrectomy with local decontamination. A prospective, randomized, double-blind, placebo-controlled multicenter trial. Ann Surg 1997; 225:172-180
16. Quinio B, Albanese J, Bues-Charbit M, et al: Selective decontamination of the digestive tract in multiple trauma patients. A prospective double-blind, randomized, placebo-controlled study. Chest 1996; 109:765-772
17. Hammond JM, Potgieter PD, Saunders GL: Selective decontamination of the digestive tract in multiple trauma patients - Is there a role? Results of a prospective, double-blind, randomised trial. Crit Care Med 1994; 22:33-39
18. Gastinne H, Wolff M, Delatour F, et al: A controlled trial in intensive care units of selective decontamination of the digestive tract with nonabsorbable antibiotics. The French Study Group on Selective Decontamination of the Digestive Tract. N Engl J Med 1992; 326:594-599
19. Blair P, Rowlands BJ, Lowry K, et al: Selective decontamination of the digestive tract: A stratified, randomized, prospective study in a mixed intensive care unit. Surgery 1991; 110:303-309
20. Kerver AJ, Rommes JH, Mevissen-Verhage EA, et al: Prevention of colonization and infection in critically ill patients: A prospective randomized study. Crit Care Med 1988; 16:1087-1093
21. Ruza F, Alvarado F, Herruzo R, et al: Prevention of nosocomial infection in a pediatric intensive care unit (PICU) through the use of selective digestive decontamination. Eur J Epidemiol 1998; 14:719-727
22. Arnow PM, Carandang GC, Zabner R, et al: Randomized controlled trial of selective bowel decontamination for prevention of infections following liver transplantation. Clin Infect Dis 1996; 22:997-1003
23. Wiener J, Itokazu G, Nathan C, et al: A randomized, double-blind, placebo-controlled trial of selective digestive decontamination in a medical-surgical intensive care unit. Clin Infect Dis 1995; 20:861-867
24. Henrion J, Schapira M, Derue G, et al: Prevention of bacterial infection using selective intestinal decontamination in patients with cirrhosis admitted to intensive care. Controlled study in 120 patients. Acta Gastroenterol Belg 1992; 55:333-340
25. Cerra FB, Maddaus MA, Dunn DL, et al: Selective gut decontamination reduces nosocomial infections and length of stay but not mortality or organ failure in surgical intensive care unit patients. Arch Surg 1992; 127:163-167
26. Rimola A, Bory F, Teres J, et al: Oral, non-absorbable antibiotics prevent infection in cirrhotics with gastrointestinal hemorrhage. Hepatology 1985; 5:463-467
27. Lykkegaard Nielsen M, Scheibel JH, Wamberg T: Septic complications in colo-rectal surgery after 24 hours versus 60 hours of preoperative antibiotic bowel preparation. I. Prospective, randomized, double-blind clinical study. Acta Chir Scand 1978; 144:523-526
28. Drew RH, Dodds Ashley E, Benjamin DK Jr, et al: Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004; 77:232-237
29. Biancofiore G, Bindi ML, Baldassarri R, et al: Antifungal prophylaxis in liver transplant recipients: A randomised placebo-controlled study. Transpl Int 2002; 15:341-347
30. Tortorano AM, Viviani MA, Pagano A, et al: Candida colonization in orthotopic liver transplantation: Fluconazole versus oral amphotericin B. J Mycologie Medicale 1995; 5:21-24
31. Lumbreras C, Cuervas-Mons V, Jara P, et al: Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J Infect Dis 1996; 174:583-588
32. Ruskin JD, Wood RP, Bailey MR, et al: Comparative trial of oral clotrimazole and nystatin for oropharyngeal candidiasis prophylaxis in orthotopic liver transplant patients. Oral Surg Oral Med Oral Pathol 1992; 74:567-571
33. Gombert ME, duBouchet L, Aulicino TM, et al: A comparative trial of clotrimazole troches and oral nystatin suspension in recipients of renal transplants. Use in prophylaxis of oropharyngeal candidiasis. JAMA 1987; 258:2553-2555
34. Tollemar J, Hockerstedt K, Ericzon BG, et al: Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study. Transplantation 1995; 59:45-50
35. Leon A, Toubas D, Renard P, et al: Diagnosis and prevention of candidiasis in intensive care patients. Agressologie 1990; 31(8 Spec No):514-518
36. Lo WK, Chan CY, Cheng SW, et al: A prospective randomized control study of oral nystatin prophylaxis for Candida peritonitis complicating continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1996; 28:549-552
37. He YM, Lv XS, Ai ZL, et al: Prevention and therapy of fungal infection in severe acute pancreatitis: A prospective clinical study. World J Gastroenterol 2003; 9:2619-2621
38. Gallin JI, Alling DW, Malech HL, et al: Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med 2003; 348:2416-2422
39. Kohl TD, Martin DC, Nemeth R, et al: Fluconazole for the prevention and treatment of tinea gladiatorum. Pediatr Infect Dis J 2000; 19:717-722
40. Kaufman D, Boyle R, Hazen KC, et al: Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001; 345:1660-1666
41. Kicklighter SD, Springer SC, Cox T, et al: Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant. Pediatrics 2001; 107:293-298
42. Wainer S, Cooper PA, Funk E, et al: Prophylactic miconazole oral gel for the prevention of neonatal fungal rectal colonization and systemic infection. Pediatr Infect Dis J 1992; 11:713-716
43. Sandven P, Qvist H, Skovlund E, et al: NORGAS Group and the Norwegian Yeast Study Group. Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations. Crit Care Med 2002; 30:541-547
44. van Weissenbruch R, Bouckaert S, Remon JP, et al: Chemoprophylaxis of fungal deterioration of the Provox silicone tracheoesophageal prosthesis in postlaryngectomy patients. Ann Otol Rhinol Laryngol 1997; 106:329-337
45. Winston DJ, Busuttil RW: Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. Transplantation 2002; 74:688-695
46. Savino JA, Agarwal N, Wry P, et al: Routine prophylactic antifungal agents (clotrimazole, ketoconazole, and nystatin) in nontransplant/nonburned critically ill surgical and trauma patients. J Trauma 1994; 36:20-25
47. Ables AZ, Blumer NA, Valainis GT, et al: Fluconazole prophylaxis of severe candida infections in trauma and postsurgical patients: Prospective, double blind, randomised, placebo controlled trial. Infect Dis Clin Pract 2000; 9:169-175
48. Jacobs S, Price Evans DA, Tariq M, et al: Fluconazole improves survival in septic shock: A randomized double-blind prospective study. Crit Care Med 2003; 31:1938-1946
49. Sharpe MD, Ghent C, Grant D, et al: Efficacy and safety of itraconazole prophylaxis for fungal infections after orthotopic liver transplantation: A prospective, randomized, double-blind study. Transplantation 2003; 76:977-983
50. Garbino J, Lew DP, Romand JA, et al: Prevention of severe Candida infections in non-neutropenic, high-risk, critically ill patients: A randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 2002; 28:1708-1717
51. Pelz RK, Hendrix CW, Swoboda SM, et al: Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001; 233:542-548
52. Winston DJ, Pakrasi A, Busuttil RW: Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 131:729-737
53. Eggimann P, Francioli P, Bille J, et al: Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999; 27:1066-1072
54. Slotman GJ, Burchard KW: Ketoconazole prevents Candida sepsis in critically ill surgical patients. Arch Surg 1987; 122(2):147-51
55. Ascioglu S, Rex JH, de Pauw B, et al: Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002; 34:7-14
56. Playford EG, Webster AC, Sorell TC, et al: Antifungal agents for preventing fungal infections in solid organ transplant recipients. Cochrane Database Syst Rev 2004; (3):CD004291
57. Bow EJ, Laverdiere M, Lussier N, et al: Antifungal prophylaxis for severely neutropenic chemotherapy recipients: A meta analysis of randomized-controlled clinical trials. Cancer 2002; 94:3230-3246
58. Kanda Y, Yamamoto R, Chizuka A, et al: Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer 2000; 89:1611-1625
59. Strahilevitz J, Sugar AM, Engelhard D: Fluconazole in transplant recipients: Options and limitations. Transpl Infect Dis 2000; 2:62-71
60. Nguyen MH, Peacock JE Jr, Morris AJ, et al: The changing face of candidemia: Emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996; 100:617-623
61. Jones BL, McLintock LA: Impact of diagnostic markers on early antifungal therapy. Curr Opin Infect Dis 2003; 16:521-526
62. Abi-Said D, Anaissie E, Uzun O, et al: The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997; 24:1122-1128
63. Wingard JR, Merz WG, Rinaldi MG, et al: Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325:1274-1277
64. Wingard JR: Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995; 20:115-125
65. Safdar A, Chaturvedi V, Koll BS, et al: Prospective, multicenter surveillance study of Candida glabrata: Fluconazole and itraconazole susceptibility profiles in bloodstream, invasive, and colonizing strains and differences between isolates from three urban teaching hospitals in New York City (Candida Susceptibility Trends Study, 1998 to 1999). Antimicrob Agents Chemother 2002; 46:3268-3272
66. Viscoli C, Girmenia C, Marinus A, et al: Candidemia in cancer patients: A prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 28:1071-1079
67. Eggimann P, Garbino J, Pittet D: Management of Candida species infections in critically ill patients. Lancet Infect Dis 2003; 3:772-785
68. Husain S, Tollemar J, Dominguez EA, et al: Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: Prospective, multicenter, case-controlled study. Transplantation 2003; 75:2023-2029